Allianz Asset Management GmbH Has $4.17 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH

Key Points

• Allianz Asset Management GmbH reduced its stake in Lantheus Holdings, Inc. by 38.2%, now holding approximately $4.17 million worth of shares after selling 31,505 during the second quarter.
• Several other hedge funds also adjusted their positions, with the State of Michigan Retirement System increasing its holdings by 0.6% in the first quarter.
• Analysts have mixed opinions on Lantheus, with price targets ranging from $70.00 to $112.00, reflecting a consensus rating of "Moderate Buy."

Allianz Asset Management GmbH trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 38.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 50,976 shares of the medical equipment provider's stock after selling 31,505 shares during the quarter. Allianz Asset Management GmbH owned approximately 0.07% of Lantheus worth $4,173,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. State of Michigan Retirement System boosted its stake in shares of Lantheus by 0.6% during the first quarter. State of Michigan Retirement System now owns 16,600 shares of the medical equipment provider's stock valued at $1,620,000 after purchasing an additional 100 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Lantheus by 36.5% during the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 116 shares in the last quarter. Intrust Bank NA boosted its stake in shares of Lantheus by 2.9% during the first quarter. Intrust Bank NA now owns 4,417 shares of the medical equipment provider's stock valued at $431,000 after purchasing an additional 125 shares in the last quarter. Focus Financial Network Inc. boosted its stake in shares of Lantheus by 4.0% during the second quarter. Focus Financial Network Inc. now owns 3,576 shares of the medical equipment provider's stock valued at $293,000 after purchasing an additional 136 shares in the last quarter. Finally, Nisa Investment Advisors LLC boosted its stake in shares of Lantheus by 2.1% during the first quarter. Nisa Investment Advisors LLC now owns 6,691 shares of the medical equipment provider's stock valued at $653,000 after purchasing an additional 139 shares in the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on LNTH shares. JMP Securities cut their price target on Lantheus from $112.00 to $73.00 and set a "market outperform" rating on the stock in a research note on Thursday, August 7th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a research note on Wednesday, July 16th. TD Cowen cut their price objective on Lantheus from $95.00 to $80.00 and set a "buy" rating on the stock in a research note on Monday, September 15th. The Goldman Sachs Group set a $77.00 price objective on Lantheus and gave the stock a "neutral" rating in a research note on Wednesday, October 8th. Finally, Mizuho cut their price objective on Lantheus from $120.00 to $70.00 and set an "outperform" rating on the stock in a research note on Thursday, August 7th. Four analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $74.50.

Insider Buying and Selling

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider directly owned 3,477,227 shares in the company, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Farallon Partners L. L. C/Ca sold 3,365,000 shares of Lantheus stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares of the company's stock, valued at approximately $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 6,812,000 shares of company stock valued at $382,427,380. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Trading Down 1.1%

Shares of LNTH stock opened at $56.51 on Friday. The company has a market cap of $3.84 billion, a P/E ratio of 15.03 and a beta of 0.09. The stock has a 50 day simple moving average of $54.10 and a two-hundred day simple moving average of $72.24. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. Lantheus Holdings, Inc. has a fifty-two week low of $47.25 and a fifty-two week high of $118.21.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The business had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.